Details of the Drug
General Information of Drug (ID: DMLW651)
Drug Name |
4-amino-N-p-tolylbenzenesulfonamide
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
4-Amino-N-(4-methylphenyl)benzenesulfonamide; 16803-95-5; 4-Amino-N-(p-tolyl)benzenesulfonamide; QXIZWXNTAVXJNC-UHFFFAOYSA-N; Benzenesulfonamide, 4-amino-N-(4-methylphenyl)-; AC1LC9K2; Oprea1_140477; CHEMBL389286; SCHEMBL2240008; CTK0E5316; DTXSID50341293; MolPort-002-788-929; ZINC265634; ALBB-005339; ZX-AN005271; BBL008295; STK288097; 4-Amino-N-p-tolyl-benzenesulfonamide; AKOS000151276; MCULE-6336197788; SEL11434898; TR-041978; TR-058746; AB0221486; ST45130422; R4223; EU-0099855; [(4-aminophenyl)sulfonyl](4-methylphenyl)amine
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 262.33 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.1 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||